Pyrukynd (Mitapivat Sulfate) Patent Expiration, LOE Window & CMS Spending
Pyrukynd (Mitapivat Sulfate) by Agios: FDA Orange Book core substance LOE 2038-11-21 (last listed 2041-07-31), 0 AB generics, $12.7M 2024 CMS Part D & Medicaid spend, and $32,610 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Agios |
| FDA Application & Pathway | N216196 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2038-11-21 |
| Last Listed Patent or Exclusivity Date | 2041-07-31 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $12.7M |
| 2024 Medicare Part D Spend | $6.0M |
| 2024 Medicaid Spend | $6.7M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($32,610 intro WAC) |